[
  {
    "ts": null,
    "headline": "AbbVie (ABBV) Reports Next Week: Wall Street Expects Earnings Growth",
    "summary": "AbbVie (ABBV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",
    "url": "https://finnhub.io/api/news?id=e348e36191adff74703e15dd1911bc697362f0832b9d5de5b8e48d92d83b9f1b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769612411,
      "headline": "AbbVie (ABBV) Reports Next Week: Wall Street Expects Earnings Growth",
      "id": 138285063,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "AbbVie (ABBV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",
      "url": "https://finnhub.io/api/news?id=e348e36191adff74703e15dd1911bc697362f0832b9d5de5b8e48d92d83b9f1b"
    }
  },
  {
    "ts": null,
    "headline": "Some of Pharma's Biggest Brands Face a New Reality",
    "summary": "A government process quietly moves forward",
    "url": "https://finnhub.io/api/news?id=48ae2d909b1bce31a2977fa3cc46c5767b5b75f264a8467010fbce54b699fc3f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769611689,
      "headline": "Some of Pharma's Biggest Brands Face a New Reality",
      "id": 138281443,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "A government process quietly moves forward",
      "url": "https://finnhub.io/api/news?id=48ae2d909b1bce31a2977fa3cc46c5767b5b75f264a8467010fbce54b699fc3f"
    }
  },
  {
    "ts": null,
    "headline": "Allergan Aesthetics Unveils New Data Across Facial Injectables On-Market and Emerging Portfolio at IMCAS 2026 Showcasing Enduring Strength in Advancing Aesthetics Medicine",
    "summary": "Allergan Aesthetics, an AbbVie company (NYSE: ABBV), today announced it will present new data from its facial aesthetics portfolio at the 2026 International Master Course on Aging Science (IMCAS) World Congress, taking place January 29–31, 2026, in Paris, France. E-posters, along with expert panels and symposiums, collectively demonstrate Allergan Aesthetics' pioneering research, new toxin innovation and commitment to advancing a multimodal approach to treatment using AA Signature™ approach.",
    "url": "https://finnhub.io/api/news?id=a1cb02a62d71a2ac553bea01bd8cac4889c67990a328e9e2782c624ff6a54dd9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769605200,
      "headline": "Allergan Aesthetics Unveils New Data Across Facial Injectables On-Market and Emerging Portfolio at IMCAS 2026 Showcasing Enduring Strength in Advancing Aesthetics Medicine",
      "id": 138280611,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Allergan Aesthetics, an AbbVie company (NYSE: ABBV), today announced it will present new data from its facial aesthetics portfolio at the 2026 International Master Course on Aging Science (IMCAS) World Congress, taking place January 29–31, 2026, in Paris, France. E-posters, along with expert panels and symposiums, collectively demonstrate Allergan Aesthetics' pioneering research, new toxin innovation and commitment to advancing a multimodal approach to treatment using AA Signature™ approach.",
      "url": "https://finnhub.io/api/news?id=a1cb02a62d71a2ac553bea01bd8cac4889c67990a328e9e2782c624ff6a54dd9"
    }
  },
  {
    "ts": null,
    "headline": "Healthy Returns: Botox, Trulicity among 15 drugs added to Medicare price negotiations",
    "summary": "The Trump administration kicked off another round of Medicare drug price negotiations, while Kaiser Permanente agrees to pay a historic settlement.",
    "url": "https://finnhub.io/api/news?id=5ae77557973ed9453fe5371e6a9ab2b8b579680df212327413d4e8b25d81b98e",
    "source": "CNBC",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769602052,
      "headline": "Healthy Returns: Botox, Trulicity among 15 drugs added to Medicare price negotiations",
      "id": 138282758,
      "image": "https://image.cnbcfm.com/api/v1/image/107188275-16753645842023-02-02t183236z_737430976_rc253z9n9jw3_rtrmadp_0_lilly-results.jpeg?v=1694350801&w=1920&h=1080",
      "related": "ABBV",
      "source": "CNBC",
      "summary": "The Trump administration kicked off another round of Medicare drug price negotiations, while Kaiser Permanente agrees to pay a historic settlement. ",
      "url": "https://finnhub.io/api/news?id=5ae77557973ed9453fe5371e6a9ab2b8b579680df212327413d4e8b25d81b98e"
    }
  },
  {
    "ts": null,
    "headline": "Exclusive-Novo's Wegovy and Ozempic US advertising spend doubles rival Eli Lilly, data shows",
    "summary": "By Harshita Mary Varghese and Patrick Wingrove Jan 28 (Reuters) - Novo Nordisk spent nearly $500 million on U.S. advertising for its GLP-1 drugs Wegovy and Ozempic in the first nine months of 2025,",
    "url": "https://finnhub.io/api/news?id=d820259e38faa5d65bd840b433fdc2658c6204f792aeefcd229d1f393beb7439",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769599881,
      "headline": "Exclusive-Novo's Wegovy and Ozempic US advertising spend doubles rival Eli Lilly, data shows",
      "id": 138279754,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "By Harshita Mary Varghese and Patrick Wingrove Jan 28 (Reuters) - Novo Nordisk spent nearly $500 million on U.S. advertising for its GLP-1 drugs Wegovy and Ozempic in the first nine months of 2025,",
      "url": "https://finnhub.io/api/news?id=d820259e38faa5d65bd840b433fdc2658c6204f792aeefcd229d1f393beb7439"
    }
  },
  {
    "ts": null,
    "headline": "Does AbbVie's Bispecific Trial Win and R&D Pledge Change The Bull Case For AbbVie (ABBV)?",
    "summary": "AbbVie recently announced topline Phase 3 results from the EPCORE DLBCL-1 trial, showing improved progression-free survival and response measures for epcoritamab versus chemoimmunotherapy in adults with relapsed or refractory diffuse large B-cell lymphoma, but without a statistically significant overall survival benefit. Alongside these data, AbbVie and Genmab plan to engage regulators on next steps, underscoring how bispecific T‑cell engagers could reshape treatment options for patients...",
    "url": "https://finnhub.io/api/news?id=e0120a851865b2e8afe609a9f06d890843f320f26f392a6972ecfd479bd48a2b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769562291,
      "headline": "Does AbbVie's Bispecific Trial Win and R&D Pledge Change The Bull Case For AbbVie (ABBV)?",
      "id": 138277114,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "AbbVie recently announced topline Phase 3 results from the EPCORE DLBCL-1 trial, showing improved progression-free survival and response measures for epcoritamab versus chemoimmunotherapy in adults with relapsed or refractory diffuse large B-cell lymphoma, but without a statistically significant overall survival benefit. Alongside these data, AbbVie and Genmab plan to engage regulators on next steps, underscoring how bispecific T‑cell engagers could reshape treatment options for patients...",
      "url": "https://finnhub.io/api/news?id=e0120a851865b2e8afe609a9f06d890843f320f26f392a6972ecfd479bd48a2b"
    }
  }
]